Mercury Biopharmaceutical (ROCO:6932) Total Equity: NT$219.67 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6932 Mercury Biopharmaceutical Corp ROCO:6932
25 GF Score
Price NT$5.93
GF Value NT$36.00
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Mercury Biopharmaceutical Total Equity?

Mercury Biopharmaceutical ROCO:6932 -2.63% 25 Total Equity is NT$219.67 Mil as of Dec. 2025. GuruFocus rates ROCO:6932 with a GF Score™ of 25/100 and a GF Value™ of NT$36.00 (Possible Value Trap). The stock has 1 warning sign investors should review.

Mercury Biopharmaceutical's total equity for the quarter that ended in Dec. 2025 was NT$219.67 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Mercury Biopharmaceutical Total Equity Historical Data

* Premium members only.

The historical data trend for Mercury Biopharmaceutical's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mercury Biopharmaceutical Total Equity Chart

Mercury Biopharmaceutical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 10.46 180.33 388.35 290.27 219.67

Mercury Biopharmaceutical Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 388.35 323.91 290.27 252.34 219.67
ROCO:6932
25GF Score
Mercury Biopharmaceutical Corp ROCO:6932
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mercury Biopharmaceutical Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Mercury Biopharmaceutical's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=278.386-58.715
=219.67

Mercury Biopharmaceutical's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=278.386-58.715
=219.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of NT$219.67 Mil mean?
Mercury Biopharmaceutical (ROCO:6932) has a Total Equity of NT$219.67 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Mercury Biopharmaceutical and its competitors.
Is Mercury Biopharmaceutical's Total Equity too high?
Mercury Biopharmaceutical's current Total Equity is NT$219.67 Mil. Overall, Mercury Biopharmaceutical has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mercury Biopharmaceutical's Total Equity compare to ZTS and UTHR?
Mercury Biopharmaceutical's Total Equity of NT$219.67 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Mercury Biopharmaceutical and its competitors. Mercury Biopharmaceutical's current Total Equity is NT$219.67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mercury Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Mercury Biopharmaceutical (ROCO:6932) is currently considered Possible Value Trap. The stock's GF Value™ is NT$36.00, compared to a current price of NT$5.93 — trading 83.5% below its estimated fair value. The current Total Equity is NT$219.67 Mil. Mercury Biopharmaceutical's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Mercury Biopharmaceutical (ROCO:6932), the current Total Equity is NT$219.67 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mercury Biopharmaceutical (ROCO:6932) Overvalued in 2026?

Based on GuruFocus' analysis, Mercury Biopharmaceutical stock appears to be undervalued. The current stock price of NT$5.93 is trading 83.5% below its estimated GF Value™ of NT$36.00. GuruFocus considers Mercury Biopharmaceutical to be Possible Value Trap.

Key valuation signals for ROCO:6932:

  • Total Equity: NT$219.67 Mil
  • GF Value™: NT$36.00 vs. price of NT$5.93 (83.5% below fair value)
  • GF Score™: 25/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6932 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mercury Biopharmaceutical Business Description

Address No. 653-1, Bannan Road, 15th Floor, Zhonghe District, New Taipei City, TWN
Mercury Biopharmaceutical Corp focuses on the development of drugs for unmet medical needs. It offers a development platform focusing on rapid release and free adjustable doses. Its 3D powder bonding method (binder jetting) combines powder and special molding adhesive and stacks them in layers.
25GF Score

Get the complete analysis for ROCO:6932

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$5.93
Price
NT$36.00
GF Value